My understanding is they are combined. Phase 1 is safety and phase 2 is efficacy. If they were doing phase 1 first they would normally use healthy volunteers. Clearly shown below 30 patients over 14 days to assess safety and efficacy. I assume the time delay is because they will not be doing all 30 patients at once, more likely only a few at any given time. After 2 weeks they should have safety and efficacy results for each patient.
From their recent announcement that approval had been received.
15 April. The Company’s clinical trial is registered under ‘Proof of Concept Study of RECCE 327 Topical Antibiotic Therapy for Infected Burn Wounds in Adults’ and involves 30 patients to assess safety and efficacy of R327. Over 14 days, 10 patients will receive R327 daily while a further 20 receive treatment three times per week. The Company looks forward to updating shareholders on the progression of this trial over the time ahead.
RCE Price at posting:
95.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)